Clinical Trials Browser

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT06485713 2024-07-03

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

Phase 2 Recruiting

200 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06379399 2024-04-23

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Phase 1/2 Recruiting

26 enrolled

Gastrointestinal

Colorectal Cancer Metastatic

NCT06202001 2024-04-02

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Phase 1/2 Recruiting

70 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Phase 2 Recruiting

116 enrolled

Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

NCT05007132 2024-02-15

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Phase 2 Recruiting

153 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06242067 2024-02-05

BEV-TASIRI

Phase 2 Recruiting

50 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05970705 2023-08-01

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

Phase 2 Recruiting

101 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

SCOTI

DEL-LIVER

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

COMBINE-EGFR-1

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

GOBLET

TRIFLUOX-DP

RAK in GC

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

TASLARC

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

LOGICAN

AB122 Platform Study

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

BEV-TASIRI

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC